What Wall Street Analysts Are Buzzing About This Morning

Trader Wall Street Computer Screen Bloomberg Terminal Staring Intently Focus

Photo: Spencer Platt/Getty Images

Good morning. Here’s your daily equity research round up from the Street.Credit Suisse:

American Tower Corp. (AMT): Credit Suisse has downgraded the company’s shares from Outperform to Neutral. They reported better than expected growth in the second quarter, leading CS to increase estimates slightly. However, the shares are edging up on the bank’s price target, prompting a downgrade on valuation. 


Aon Corp. (AON): Citi has raised its price target for the risk management company from $34 to $39. The revision comes after the company beat expectations for its second quarter results. Citi’s takeaway from the earnings was that the company’s brokerage business is performing nicely, and management seems to be doing a good job working through a difficult period for HR solutions. 

Deutsche Bank:

Johnson & Johnson (JNJ): It was announced yesterday that an experimental Alzheimer’s drug being developed by a Johnson and Johnson subsidiary did not meet its endpoint in two different studies. Further studies are being discontinued. Deutsche Bank expects a limited decline in J&J shares of a couple per cent at most, and a small drop in Baxter’s stock as investors reduce expectations for Alzheimer’s programs. 

Don’t miss: The 12 Most Infamous Economic Conspiracy Theories

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.

Tagged In